ProShare Advisors’s Genmab GMAB Stock Holding History

ProShare Advisors’s Portfolio GMAB Stock Details GMAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-6,608	Closed	-$261K	–	2236
2021 Q4	$261K	Sell	6,608 -3,682	-36%	-$154K	﹤0.01%	1871
2021 Q3	$450K	Buy	10,290 +1,685	+20%	+$75.6K	﹤0.01%	1267
2021 Q2	$351K	Buy	8,605 +1,978	+30%	+$76.3K	﹤0.01%	1781
2021 Q1	$218K	Sell	6,627 -432	-6%	-$16.2K	﹤0.01%	1988
2020 Q4	$287K	Buy	7,059 +155	+2%	+$5.79K	﹤0.01%	1647
2020 Q3	$253K	Buy	+6,904	New	+$250K	﹤0.01%	1292

Other funds holding GMAB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

1832 Asset Management Toronto, Ontario, Canada $109B AUM 35.56% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

HJGA

Hardman Johnston Global Advisors Stamford, Connecticut $2.1B AUM 41.89% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

ProShare Advisors's GMAB Position: Q1 2022 in Review

ProShare Advisors sold out of Genmab (GMAB) in Q1 2022, closing a stake of 6,608 shares — an estimated $261K sold.

ProShare Advisors first reported a position in GMAB in Q3 2020 and held it in 6 quarters. The position peaked at $450K in Q3 2021. 204 funds tracked by Wall St. Rank hold GMAB as of Q1 2022.

ProShare Advisors reported no remaining Genmab position as of Q1 2022 after selling out during the quarter.
ProShare Advisors sold 6,608 Genmab shares in Q1 2022, an estimated $261K.
ProShare Advisors first reported a position in Genmab in Q3 2020 and held it in 6 quarters.
ProShare Advisors's Genmab position peaked at $450K in Q3 2021.
204 funds tracked by Wall St. Rank held Genmab as of Q1 2022.

Based on ProShare Advisors's 13F filing for Q1 2022, filed 10 May 2022.